耀才团队: 恒指将下试26,000点关口之支持
耀才证券研究部团队称,美股隔晚(24日)先升後跌,虽然中美高级别贸易谈判将於两星期後召开,消息带动三大指数早段上升,但特朗普於联合国发言对中国态度表现强硬,其後投资者关注民主党宣布向总统特朗普展开正式弹劾调查,加上消者费信心指数令市场失望,都打击市场气氛,拖累市况倒跌。港股ADR跟随美股回落,恒指今早(25日)或先行低开200点左近,将下试26,000点关口支持。
药股昨日表现波动,受带量采购消息影响,昨日此板块先跌後回升,第二轮带量采购招标结果已於昨日公布,与「4+7」试点首轮带量采购的中选价格水平比较,今次中选的药价平均跌幅达25%,药价的平均跌幅略高於券商预期,药股短期後市在政策风险影响下,目前宜采取观望态度。
从技术上看,恒指自9月23日跌穿20天线後,整个形态已进一步转差,亦意味恒指自8月15日低位24,899点开始之反弹,或已止步於9月13日高位27,366点。故目前投资者宜加倍小心,如恒指进一步失守26,000点心理关口,整个反覆向下寻底之格局很大可能重现。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.